Suchergebnisse - "Asefy, Zahra"

PubPharm (14)

1

COVID-19 vaccines : Current evidence and considerations

enthalten in: Metabolism open | 2021

von Tavilani, A. | Abbasi, E. | Kian Ara, F. | +2

2

miR-515-3p, miR-623, miR-1272 and Notch3 protein as new biomarkers of Hepatocellular carcinoma

enthalten in: Hormone molecular biology and clinical investigation | 2021

von Asefy, Z. | Hoseinnejhad, S. | Eftekhari, A. | +1

3

miR-515-3p, miR-623, miR-1272 and Notch3 protein as new biomarkers of Hepatocellular carcinoma

enthalten in: Hormone molecular biology and clinical investigation | 2021

von Asefy, Z. | Hoseinnejhad, S. | Eftekhari, A. | +1

4

Melatonin hormone as a therapeutic weapon against neurodegenerative diseases

enthalten in: Cellular and molecular biology (Noisy-le-Grand, France) | 2021

von Asefy, Z. | Khusro, A. | Mammadova, S. | +7

5

Prolactin and susceptibility to COVID-19 infection

enthalten in: Medical hypotheses | 2021

von Mirzaei, F. | Tavilani, A. | Asefy, Z. | +1

CommentOn: Med Hypotheses. 2020 Nov;144:110208. - PMID 33254515

6

Nanoparticles approaches in neurodegenerative diseases diagnosis and treatment

enthalten in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology | 2021

von Asefy, Z. | Hoseinnejhad, S. | Ceferov, Z.

7

Nanoparticles approaches in neurodegenerative diseases diagnosis and treatment

enthalten in: Neurological sciences | 2021

von Asefy, Z. | Hoseinnejhad, S. | Ceferov, Z.

8

Nanoparticles approaches in neurodegenerative diseases diagnosis and treatment

enthalten in: Neurological sciences | 2021

von Asefy, Z. | Hoseinnejhad, S. | Ceferov, Z.

9

Nanoparticles approaches in neurodegenerative diseases diagnosis and treatment

enthalten in: Neurological sciences | 2021

von Asefy, Z. | Hoseinnejhad, S. | Ceferov, Z.

10

Unsaturated fatty acids as a co-therapeutic agents in cancer treatment

enthalten in: Molecular biology reports | 2021

von Asefy, Z. | Tanomand, A. | Hoseinnejhad, S. | +3